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Abstract 
Background: Up‑to‑date identification of local trends in sepsis incidence and outcomes is of considerable public 
health importance. The aim of our study was to estimate annual incidence rates and in‑hospital mortality trends for 
hospitalized patients with sepsis in a European setting, while avoiding selection bias in relation to different complexity 
hospitals.
Methods: A large retrospective analysis of a 5‑year period (2008–2012) was conducted of hospital discharge records 
obtained from the Catalan Health System (CatSalut) Minimum Basic Data Set for Acute‑Care Hospitals (a mandatory 
population‑based register of admissions to all public and private acute‑care hospitals in Catalonia). Patients hospital‑
ized with sepsis were detected on the basis of ICD‑9‑CM codes used to identify acute organ dysfunction and infec‑
tious processes.
Results: Of 4,761,726 discharges from all acute‑care hospitals in Catalonia, 82,300 cases (1.72%) had sepsis diagnoses. 
Annual incidence was 212.7 per 100,000 inhabitants/year, rising from 167.2 in 2008 to 261.8 in 2012. Length of hos‑
pital stay fell from 18.4 to 15.3 days (p < .00001), representing a relative reduction of 17%. Hospital mortality fell from 
23.7 to 19.7% (p < .0001), representing a relative reduction of 16.9%. These differences were confirmed in the multi‑
variate analysis (adjusted for age group, sex, comorbidities, ICU admission, emergency admission, organ dysfunction, 
number of organ failures, sepsis source and bacteraemia).
Conclusions: Sepsis incidence has risen in recent years, whereas mortality has fallen. Our findings confirm reports for 
other parts of the world, in the context of scarce administrative data on sepsis in Europe.
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Background
Sepsis has been recently redefined as an infection that 
leads to organ dysfunction [1]. Although a hospitalized 
patient with sepsis is more likely to die than a patient 
with heart attack or stroke [2], sepsis is still not evaluated 
with the same urgency as other critical conditions. Sepsis 
mortality can be reduced considerably by adopting early 
recognition protocols and using standardized emergency 
treatment, but fewer than 1 in 7 patients are actively 
intervened in this way [3]. Treatment ineffectiveness is 
often due to late sepsis diagnosis—mainly a failure by 
caregivers or healthcare professionals to suspect sepsis. 
The clinical symptoms and laboratory signs currently 
used for diagnostic purposes are not specific for sepsis, 
and there is a lack of reliable systems for timely detection 
of septic patients.
Proper detection of sepsis and its progression are essen-
tial to patient management. Epidemiology case studies 
using administrative hospital data have reported both 
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growing incidence and declining mortality rates associ-
ated with severe sepsis in several different countries but 
mainly in the USA, Australia and New Zealand [4–11]. 
However, administrative data may be affected by changes 
in coding practices that distort incidence and mortal-
ity estimates. Recently, Stevenson et  al. [12] compared 
incidence and mortality trends in trial data with those 
observed in administrative data, observing that, since 
1991, risk-standardized 28-day severe sepsis mortality has 
tended to decline in parallel for both methods; this which 
would indicate that trends in severe sepsis mortality as 
calculated from administrative data and International 
Classification of Diseases, 9th revision, Clinical Modifica-
tion (ICD-9-CM) algorithms are likely to be accurate.
Catalonia, an autonomous region in Spain, has actively 
begun to advocate more vigorous efforts to decrease the 
sepsis burden through the development of an Inter-hos-
pital Sepsis Emergency Code, operational between the 
Catalan Health Service (CatSalut) and seven local medi-
cal societies [13]. Since the identification of trends in sep-
sis outcomes is of considerable public health importance, 
the aim of our study was to estimate population and 
annual in-hospital incidence rates and in-hospital mor-
tality trends for patients with sepsis between 2008 and 
2012 in Catalonia, before implementation of the Inter-
hospital Sepsis Emergency Code designed to coordinate 
and optimize care of patients with sepsis.
Methods
Data sources
A retrospective analysis was conducted of hospital dis-
charge records from the Minimum Basic Data Set for the 
Catalan Health System (CatSalut) Acute-Care Hospitals 
(a mandatory population-based register of admissions to 
all public and private acute-care hospitals in Catalonia) 
enables evaluation and optimization of resource use, pro-
vides support to and improves healthcare planning and 
facilitates procurement management and payments. To 
ensure data quality, the CMBD-HA input data are sys-
tematically validated internally and periodically vali-
dated externally. The data set contains demographic and 
clinical data for patient care episodes, including age, sex, 
length of stay (days), one primary diagnosis, up to nine 
secondary diagnoses, one primary procedure, up to seven 
secondary procedures and status on discharge (alive or 
dead). Official data from the register of insured persons 
maintained by CatSalut were used to estimate crude 
and specific hospitalization rates (universal coverage for 
7,601,813 inhabitants in 2012).
Patients
Sepsis, formerly severe sepsis [1] was defined by the pres-
ence of infection and at least one organ dysfunction. 
Patients hospitalized with sepsis were detected, according 
ICD-9-CM codes used to identify acute organ dysfunction 
and infectious processes following the Angus methodology 
[5], over a 5-year period (2008–2012). To avoid overlaps, we 
excluded patients who were transferred from one acute-care 
hospital to another during the same severe sepsis episode.
Coding
Diagnoses and procedures were coded using the ICD-
9-CM, whose codes to identify patients with sepsis were 
updated in 2000 to the following: 995.91 (sepsis), 995.92 
(severe sepsis) and 785.52 (septic shock) (Supplemen-
tary Appendix: Additional file  1). Although information 
was not available regarding the unit or department where 
patients were treated (intensive care unit (ICU), internal 
medicine unit, etc.), we indirectly deduced ICU admission 
from procedures typically used in intensive care manage-
ment (Supplementary Appendix: Additional file  1). The 
Charlson comorbidity index with its 17 comorbid disease 
categories [13] was used to assess the presence of underly-
ing comorbidities. The ICD-9-CM codes used to identify 
acute organ dysfunction and infectious processes are listed 
in Supplementary Appendix: Additional file 1.
Statistical analysis
The hospitalization rate was defined as the yearly number 
of admissions per 100,000 population (excluded were 1590 
admissions from non-residents in Catalonia). Crude over-
all and specific hospitalization rates by age and sex were 
calculated. Continuous variables and discrete variables 
were compared using analysis of variance and the Chi-
square test, respectively. Multivariate logistic regression, 
adjusted for other significant variables, was used to analyse 
hospital mortality risk by year of admission for the study 
population and for the ICU and non-ICU patient groups; 
variables were entered one by one and retained when their 
significance was <.10 and were clinically plausible. For the 
regression analysis, each of the clinical attributes included 
(comorbidities, acute organ failure and infection) were 
treated as binary (dummy) variables indicating the presence 
or absence of these conditions; a single patient could there-
fore account for more than one attribute. The area under 
the receiver operating characteristic curve (AUROC) was 
used to evaluate how well the multivariate logistic regres-
sion model discriminated between patients with severe 
sepsis who were discharged alive versus those who died in-
hospital [14]. Data analysis was performed using SPSS 18.0 
software (SPSS Inc, Chicago, IL, USA).
Results
Incidence and main features of severe sepsis
Of 4,761,726 discharges from all acute-care hos-
pitals during the study period, 82,300 (1.72%) had 
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sepsis. Demographic characteristics and comorbidities 
for patients with sepsis are shown in Table 1.
Annual incidence in the population was 212.7 per 
100,000 inhabitants/year, increasing from 167.2 in 2008 
to 261.8 per 100,000 inhabitants/year in 2012 (Fig.  1). 
Sepsis was significantly associated with age (more fre-
quent in older patients) and sex (208.3 cases for men ver-
sus 156.0 cases for women per 100,000 inhabitants/year) 
(Fig. 2).
The most frequent origins of sepsis were urinary and 
respiratory tract infections, accounting for 37.2 and 
32.5% of cases, respectively, followed by the abdomen 
(11%). Almost a quarter (24.7%) of cases presented bacte-
raemia. Acute kidney injury was the most frequent organ 
failure (58.4%), followed by respiratory failure (20.5%) 
and central nervous system failure (19.7%). Cardiovas-
cular dysfunction was reported in 4.9% of cases. Two or 
more acute organ failures were documented in 14% of 
cases (Table 1).
Hospital outcomes
In-hospital mortality over the study period was 21.6% 
(95% confidence interval (CI); 18.6–24.9). Hospital mor-
tality was higher in older patients with higher Charlson 
comorbidity score, in patients with bacteraemia (39.3% in 
patients with positive versus 15.8% in patients with nega-
tive blood cultures), and was also higher in patients with 
more organ failures (three or more, 63.4%). Respiratory 
and abdominal origins were associated with higher mor-
tality (24 and 28%, respectively). Mean (SD) length of stay 
was 16.7 (19.5) days, with no clinically relevant differ-
ences for patients who died in-hospital versus who were 
discharged alive (despite a value of p < .001) (Table 1 and 
Table 2).
Incidence and in‑hospital outcome trends
Incidence of sepsis increased in the five-year study 
period from 12,809 cases to 20,228 cases (mean 16,460 
cases per year over the period), representing 1.3 and 2.1% 
(p  <  .0001) of hospital admissions, respectively (Fig.  2). 
Observed in the same period were an increase in mean 
age, from 69.1 to 72.8 years (p <  .0001), and an increase 
in mean Charlson comorbidities score, from 4.9 to 5.3 
(p < .001) (Fig. 3).
Length of hospital stay decreased from 18.4 to 15.3 days 
(p  <  .0001), representing a relative reduction of 17% 
(Fig. 3). Univariate analysis showed that hospital mortal-
ity also decreased—from 23.7 to 19.7% (p  <  .0001)—for 
a relative reduction of 18.6% (Fig.  2). These differences 
were confirmed in the multivariate analysis adjusted for 
all significant variables (age group, sex, comorbidities, 
ICU admission, emergency admission, organ dysfunction, 
number of organ failures, infection source and presence 
of bacteraemia) (Tables  1, 2). Differences between 2008 
and all the ensuing years except 2009 were statistically 
significant. The logistic regression (reference year 2008) 
indicated a mortality odds ratio (OR) for patients with 
sepsis in 2012 of 0.772 (95% CI 0.727–0.820) (Table  3). 
The falling trend in the mortality OR was linear through-
out the study period for all patients with sepsis, whether 
or not treated in the ICU. Values for the AUROC were 
calculated to evaluate how well the multivariate logistic 
regression model discriminated between patients dis-
charged alive and discharged dead: 0.782 (95% CI 0.779–
0.786) for all patients, 0.746 (0.741–0.752) for non-ICU 
patients and 0.749 (0.743–0.756) for ICU patients.
Discussion
Most epidemiological data on sepsis refers to the first 
decade of twenty-first century and almost exclusively 
refer to the USA. This is a large observational study 
of patients discharged from all national health system 
acute-care hospitals conducted in a European setting. 
We estimated the mean sepsis incidence to be 212.7 cases 
per 100,000 inhabitants/year and in-hospital mortality to 
be 21.6%. Incidence and mortality varied over time, with 
a yearly increase in incidence of 7.3%, a yearly relative 
reduction of 3.3% in length of stay and a yearly reduc-
tion in in-hospital mortality of 3.4%. After adjustments 
for relevant clinical and epidemiological variables, the 
reduction in mortality remained statistically significant.
The estimated incidence of sepsis in our study was 
lower than reported in the USA and slightly higher than 
reported in smaller European studies [2, 6, 7]. Previ-
ous studies conducted in Spain reported incidences of 
between 110 and 230 cases per 100,000 inhabitants/year 
[15, 16], versus the 212.7 cases observed in our study. Dif-
ferences in calculated incidences may be related to struc-
tural or functional organization [17] or may be due to 
discharge diagnosis coding. Nonetheless, we would like 
to emphasize the importance of using local data to moni-
tor trends in activity and results over time. Moreover, 
the number of sepsis cases in our study increased yearly, 
a finding which is consistent with findings reported in 
other epidemiological studies [10–12].
Estimates of sepsis incidence and trends are also essen-
tial to estimate the resources needed to care for these 
patients. Sepsis incidence is increasing compared to inci-
dence for other leading causes of mortality such as acute 
myocardial infarction or ischaemic stroke. The CatSalut 
data on hospital admissions/year for severe sepsis (five-
year mean, 16,460 cases) are close to the combined num-
bers for acute coronary syndrome and ischaemic stroke 
admissions together, at 11,000 and 8000, respectively [18, 
19]. However, incidence rates for acute coronary syn-
drome and ischaemic stroke, unlike for sepsis, are stable 
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[19–21]. In the USA, the percentage of septic patients 
with a fatal outcome increased from 14% in 2000 to 16% 
in 2010; in contrast, mortality for respiratory failure 
decreased from 25 to 17%, for heart attack from 10 to 8%, 
for cancer from 8 to 4% and for stroke from 6 to 5% [22].
Prospective versus retrospective analysis observed 
differences in incidence and source of sepsis. Prospec-
tive monitoring is laborious, costly and complex and 
can also be affected by issues such as inclusion criteria 
or data sources [23, 24]. Although retrospective analy-
ses from hospital discharges—as in our study—can also 
be affected by definitions, codes and analytical meth-
ods, they serve an important function in analysing local 
trends and outcomes. Gaieski [24] observed a 3.5-fold 
difference in estimates of absolute incidence using differ-
ent database abstraction methods. Nonetheless, trends 
were similar irrespective of the methodology. Stevenson 
et al. [12] recently found that severe sepsis mortality was 
10% higher for patients included in the control group of 
clinical trials compared to administrative data (collected 
according to Angus’ criteria) [5]; nonetheless, mortality 
trends were similar, irrespective of the data source—and 
were also similar to the 3% yearly reduction found in 
our study. Stevenson et  al. consequently concluded that 
administrative data are useful in monitoring mortality 
trends in patients with severe sepsis.
Table 1 Profile of patients with severe sepsis in Catalonia 2008–2012





Mean (SD) Mean (SD) Mean (SD)
Age (years) 71.2 (19.7) 70.6 (20.4) 73.3 (16.6) <.0001
Length of hospital stay (days) 16.7 (19.5) 16.8 (19.3) 16.3 (20.3) <.001
Charlson comorbidity index 5.1 (2.6) 5.0 (2.6) 5.6 (2.7) <.0001
% % % p
Age (years)
 <15 3.2 3.7 1.4 <.0001
 15–44 6.1 6.6 4.2
 45–64 16.4 16.2 17.3
 65–74 17.5 17.3 18.4
 75–84 32.9 32.8 33.6
 >84 23.8 23.5 25.0
Sex
 Males 56.7 56.1 59.0 <.0001
Comorbidities
 Chronic kidney disease 23.8 24.5 20.9 <.0001
 COPD 22.4 22.9 20.6 <.0001
 Cancer 14.5 12.5 21.5 <.0001
 Metastasis 4.8 5.8 8.3 <.0001
 Peripheral vascular disease 4.4 4.2 4.9 <.0001
 Complicated diabetes 4.0 4.3 3.0 <.0001
 Liver disease: mild 9.7 8.7 13.1 <.0001
 Liver disease: moderate–severe 3.0 2.4 4.9 <.0001
 Myocardial infarction 3.8 3.6 4.7 <.0001
 Congestive heart failure 20.1 19.1 23.8 <.0001
 Cerebrovascular disease 6.7 6.5 7.6 <.0001
 AIDS/HIV infection 1.0 0.9 1.3 <.0001
Emergency stay (%) 89.4 89.8 87.8 <.0001
ICU admissions 28.2 22.3 49.8 <.0001
Admission year
 2008 15.6 15.1 17.1 <.0001
 2009 17.9 17.4 19.6
 2010 19.7 19.6 20.0
 2011 22.3 22.6 21.0
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Table 1 continued
% % % p
 2012 24.6 25.2 22.3
Sepsis origins
 Urinary 37.2 41.1 23.0 <.0001
 Respiratory 32.5 31.4 36.4 <.0001
 Abdominal 11.0 10.1 14.3 <.0001
 Skin and soft tissues 4.1 4.2 3.9 .06
 Endocarditis 1.6 1.5 2.0 <.0001
 Device‑related 1.1 1.2 0.6 <.0001
 CNS 0.9 0.9 1.2 <.0001
 Others 37.9 41.0 26.5 <.0001
Bacteraemia 24.7 19.1 44.9 <.0001
Organ dysfunction
 Kidney 58.4 56.9 63.7 <.0001
 Lung 20.5 15.7 37.9 <.0001
 CNS 19.7 21.6 12.7 <.0001
 Haematologic 11.1 11.0 11.5 .054
 Cardiovascular 4.9 5.2 3.6 <.0001
 Liver 1.3 0.7 3.3 <.0001
Number of organ failures
 1 86.3 89.7 72.9 <.0001
 2 12.0 9.4 21.8
 3 1.6 0.8 4.7
 4 or more 0.2 0.1 0.6
Data are presented as mean and standard deviation or %
AIDS acquired immune deficiency syndrome, CNS central nervous system, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, ICU 
intensive care unit
Fig. 1 Number of cases, mortality rates and hospital incidence rates for sepsis in Catalonia (2008–2012). Incidence of sepsis increased from 12,809 
cases to 20,228 cases in the 5‑year study period (mean 16,460 cases per year), representing 1.3 and 2.1% (p < .0001) of hospital admissions and an 
average yearly increase of 6%. However, hospital mortality decreased from 23.7 to 19.7% (p < .0001) for a yearly relative reduction of 3.4%
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Fig. 2 Age‑specific incidence and mortality rates for all cases of severe sepsis by sex in Catalonia (2008–2012). The dark line represents incidence 
(thicker for men and thinner for women) expressed as a thousand cases per 100,000 inhabitants. Age‑adjusted mortality is expressed as the number 
of deaths with respect to the number of cases grouped according to 5‑year age brackets
Table 2 Overall mortality by  patient characteristics, sepsis origins, presence of  bacteraemia and  organ dysfunction 
by year of admission in Catalonia (2008–2012)
Data are presented as number of cases or %
CNS central nervous system, NS non-significant
Condition N Presence of condition (%) In‑hospital 
mortality (%)
2008 2009 2010 2011 2012 p
Mortality 23.7 23.6 22.0 20.4 19.7 <.0001
Source of sepsis
 Urinary tract 30,600 33.6 35.0 37.1 39.8 38.8 <.0001 13.9
 Respiratory tract 26,748 34.2 34.0 31.2 30.9 32.7 <.0001 24.2
 Abdomen 9065 10.7 11.2 11.3 11.0 10.9 NS 28.0
 Skin and soft tissues 3394 3.9 4.0 4.0 4.4 4.2 NS 20.3
 Endocarditis 1326 1.8 1.8 1.9 1.4 1.4 <.0001 27.3
 Device‑related 869 1.1 1.1 1.2 1.1 0.9 .016 11.6
 CNS 775 1.2 1.1 1.1 0.7 0.7 <.0001 27.5
 Other 31,149 37.4 37.5 39.2 38.1 37.1 .001 15.1
Bacteraemia 20,285 25.5 25.5 24.5 24.8 23.5 <.0001 39.3
Organ dysfunction
 Kidney 48,072 50.8 53.5 57.1 61.9 64.7 <.0001 23.6
 Respiratory 16,876 26.1 24.1 20.9 17.9 16.3 <.0001 40.0
 CNS 16,177 20.5 19.6 19.1 18.9 20.3 <.0001 13.9
 Haematologic 9158 11.6 12.3 12.2 11.2 9.1 <.0001 22.4
  Cardiovascular 3988 5.3 5.4 4.7 4.6 4.4 <.0001 16.1
  Liver 1058 1.0 1.3 1.3 1.3 1.4 .029 55.9
Number of organ failures
 1 70,874 86.6 85.9 86.5 86.0 85.8 NS 18.5
 2 9964 11.7 12.2 11.8 12.4 12.3 39.0
 3 or more 1462 1.7 1.9 1.9 1.7 1.8 63.4
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Length of stay and mortality both decrease yearly dur-
ing the study period—to a statistically significant degree 
according to the multivariate analysis adjusted for demo-
graphic data, comorbidities, infection source and number 
of organ failures. The external validity of our findings is 
supported by the fact that mortality in 2008 was the same 
as that reports by the PROWESS-SHOCK study placebo 
group [25]. Other recent large randomized clinical trials 
Fig. 3 Trends for main characteristics and hospital stay for patients with sepsis in Catalonia (2008–2012)
Table 3 Univariate and multivariate analyses of in-hospital mortality by year of admission in Catalonia (2008–2012)
Data are presented as number of death or %. The multivariate analysis is adjusted by sex, age group, comorbidities, ICU admission, emergency admission, organ 
dysfunction, number of organ failures, septic origins and bacteraemia
CI confidence interval, ICU intensive care unit, OR odds ratio, NS non-significant
Univariate analysis Multivariate analysis
N % mortality p OR 95% CI for OR p
All patients N = 82,300
 2008 12,809 23.7 <.0001 1 – –
 2009 14,736 23.6 0.988 0.928–1.052 NS
 2010 16,192 22.0 0.911 0.856–0.969 .003
 2011 18,335 20.4 0.818 0.770–0.870 <.0001
 2012 20,228 19.7 0.772 0.727–0.820 <.0001
Non‑ICU patients N = 59,064
 2008 8551 15.8 <.0001 1 – –
 2009 10,137 16.3 1.028 0.945–1.117 NS
 2010 11,497 15.4 0.941 0.867–1.022 NS
 2011 13,545 14.8 0.859 0.793–0.931 <.0001
 2012 15,334 13.9 0.769 0.711–0.832 <.0001
ICU patients N = 23,236
 2008 4258 39.5 .002 1 – –
 2009 4599 39.6 0.938 0.854–1.031 NS
 2010 4695 38.2 0.868 0.790–0.953 .003
 2011 4790 36.0 0.757 0.686–0.832 <.0001
 2012 4894 37.6 0.778 0.702–0.855 <.0001
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(RCTs) have reported mortality rates of 18–30% [26, 27], 
further confirming the likely validity of 2008 as our base-
line year. Kaukonen et  al. [11], who recently reported 
similar results for Australia and New Zealand, observed 
an annual absolute decrease of 1.3% in risk, from 24% in 
2008 to 19% in 2012. In our study, multivariate analysis 
revealed a robust association between mortality and year 
of detection, as adjusted for confounding factors including 
sex, age group, comorbidities, ICU admission, emergency 
admission, organ dysfunction, number of organ failures, 
septic focus and the presence of bacteraemia. Although 
our study was not designed to address this issue, a poten-
tial improvement in the management of sepsis could be 
suggested, explained in part as a consequence of training 
and increased clinical awareness [3, 28–30].
Our results suggest also that sepsis outcomes should 
be interpreted according to the year of data collection 
and the presence of comorbidities. Moreover, under-
powered RCTs would be avoided if these effects were 
taken into account in estimating statistical power and 
sample size. Yearly reduction in crude mortality rates 
should be expected, bearing in mind that overestimated 
mortality rates may lead to underpowered studies which 
might, in turn, lead to potentially useful treatments 
being downgraded due to lack of evidence. Furthermore, 
excluding elderly patients and patients with comorbidi-
ties from RCTs represents a form of selection bias; Kau-
konen et al. [11], for instance, reported a 4.6% mortality 
rate for comorbidity-free patients and young patients 
(versus our rate of 21.6%). Another issue is that sepsis 
outcomes are too often viewed as binary: The patient 
dies (failure) or survives (success). Studies also tend to 
focus on in-hospital mortality and length of stay as an 
outcome measure for ICU patients, overlooking the 
fact that many patients admitted for sepsis die after dis-
charge. There is an unmet need to improve knowledge 
regarding long-term effects in patients with sepsis [1–8], 
so other outcome indicators such as long-term morbid-
ity and quality of life are likely to be included in future 
trials.
Just under a quarter (24.7%) of our patients presented 
with bacteraemia, associated with higher mortality. 
Patients with bacteraemia could represent a suitable pop-
ulation to monitor prospectively in clinical practice, as 
bacteraemia, unlike sepsis, is easily identified retrospec-
tively, is easily distinguished from other non-infectious 
diseases that cause organ dysfunction and is also easily 
stratified using the sepsis-related organ failure assess-
ment (SOFA) instrument [31].
The main strengths of our study are the large cohort of 
patients included in a European setting, the fact of includ-
ing 100% of admissions to both public and private hospi-
tals of Catalonia Health System, the long period of data 
collection and the use of a previously validated strategy. 
Our study has several limitations. The fact that cases of 
sepsis were identified indirectly using ICD-9-CM codes 
implies less accuracy in identifying cases and a poor clini-
cal analysis compared to prospective methods. Urinary 
infections appear as the main focus of sepsis in our study. 
The relevance of each focus can be affected by population 
characteristics or methodology. It also can affect incidence 
or severity results. Case recruitment may also have been 
affected by coding, as reflected in our results for cardiovas-
cular dysfunction. Hypotension was poorly documented 
on discharge. Incidence, as reported in our study, probably 
does not reflect clinical incidence. Cardiovascular dys-
function incidence rates of 7.2–42% have been reported 
for epidemiological or retrospective studies, in contrast 
to rates of up 90% for prospective studies [4, 5, 9, 13, 15, 
32, 33]. Our study cannot account for reasons for reduced 
mortality and shorter stays. Inclusion of a specific severity 
scores, such as SOFA, in the multivariate analysis would 
allow insights into whether mortality reduction is related 
to the inclusion of less severe patients. Unfortunately, our 
study design does not admit this conclusion. Given that 
the CMBD-HA does not specifically collect data about 
ICU admission, the category ‘ICU stay’ was deduced from 
procedures typically used in ICUs. We think that since this 
definition is highly specific but not sensitive, we cannot 
rule out the possibility that some septic patients with less 
severity were excluded from ICU admission.
Conclusions
Sepsis incidence has risen continuously in recent years in 
Catalonia. While mortality and length of stay have fallen, 
despite increases in age and in comorbidities, our find-
ings corroborate results reported for other parts of the 
world, in the context of scarce administrative data on 
sepsis in Europe.
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